AZAINDAZOL- ODER DIAZAINDAZOLDERIVATE ALS ARZNEIMITTEL

European patent · EP2668184 · In force

Register entry

Publication number
EP2668184
Application number
EP12701884
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jan 27, 2012
Published
Dec 4, 2013
Granted
Jan 10, 2018
Protection ends at the latest
Jan 26, 2032
Next annual fee due
Jan 31, 2027
IPC classes
C07D 471/04 (2006.01)
A61K 31/4162 (2006.01)
A61P 35/00 (2006.01)
Priority
FR 1150651 27.01.2011
PCT application
PCT/EP2012/051283 27.01.2012
PCT publication
WO2012/101239 02.08.2012
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Feb 1, 2026

    Change

    Published in Swissreg on 01.02.2026

  2. Feb 1, 2025

    Change

    Published in Swissreg on 01.02.2025

  3. Feb 1, 2024

    Change

    Published in Swissreg on 01.02.2024

  4. Feb 1, 2023

    Change

    Published in Swissreg on 01.02.2023

  5. Feb 17, 2018

    Agent entered

    Representative
    MICHELI & CIE SA, 122, Rue de Genève, Case postale 61, 1226 Thônex

    Published in Swissreg on 17.02.2018

  6. Jan 10, 2018

    Granted

    Published in Swissreg on 10.01.2018

Parties

Holder

Pierre Fabre Médicament

92100 Boulogne-Billancourt, FR

Agent

MICHELI & CIE SA

122, Rue de Genève Case postale 61, 1226 Thônex

Inventor

KALOUN, El Bachir

F-31120 Roquettes, FR

BEDJEGUELAL, Karim

F-31400 Toulouse, FR

RABOT, Rémi

F-31400 Toulouse, FR

KRUCZYNSKI, Anna

F-31450 Pompertuzat, FR

SCHMITT, Philippe

Nailloux 31560, FR

PEREZ, Michel

F-81100 Castres, FR

RAHIER, Nicolas

F-31450 Ayguesvives, FR

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.